Becton Dickinson and Co at Barclays Global Healthcare Conference Transcript
All right. Well, good morning, everybody. My name is Matt Miksic at Barclays. I cover U.S. Medical Devices. We're super pleased to have with us this morning part of the management team here from Becton, Dickinson. We have Chris DelOrefice, EVP and CFO; and Dave Hickey, EVP and President of Life Sciences.
I wanted to first thank you both for coming. And it's my first year at this conference and it's been great so far. I wanted to take sort of like a little bit of a higher level view of the company, kind of step through what's driving the growth and what's driving the margin benefits that you've been able to deliver, in part because on the growth side, for a traditional Becton, Dickinson, I think a lot of people have been surprised, intrigued, and maybe a little skeptical that you can maintain this kind of higher tier of growth that you've started to deliver in the last couple of years.
And then on the margin side, I think it's notable that in the landscape of medical device companies that are all facing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |